Literature DB >> 16007883

Autologous transplantation in relapsed and refractory Hodgkin's disease.

Andreas Josting1.   

Abstract

The current data support the use of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as standard procedure for the majority of patients with Hodgkin's disease (HD) relapsing or progressing after combination chemotherapy. Prognostic factors reflecting unfavourable prognostic features of the disease as well as resistance to conventional salvage therapy have been identified. Preliminary data suggests a high efficacy of high-dose sequential chemotherapies in these patients. An ongoing randomized trial is comparing standard HDCT versus sequential HDCT in patients with relapsed HD.

Entities:  

Mesh：

Year:  2005        PMID： 16007883     DOI： 10.1111/j.1600-0609.2005.00468.x

Source DB:  PubMed          Journal:  Eur J Haematol Suppl        ISSN： 0902-4506


  3 in total

1.  Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.

Authors:  Peter D Cole; Kathleen M McCarten; Richard A Drachtman; Pedro de Alarcon; Lu Chen; Tanya M Trippett; Cindy L Schwartz
Journal:  Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.969

2.  Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.

Authors:  Peter D Cole; Cindy L Schwartz; Richard A Drachtman; Pedro A de Alarcon; Lu Chen; Tanya M Trippett
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

3.  Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma.

Authors:  Angelo Michele Carella
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-02       Impact factor: 2.576
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.